¼¼°èÀÇ ·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â ½ÃÀå
Rheumatoid Arthritis Diagnostic Devices
»óǰÄÚµå : 1795335
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 170 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â ¼¼°è ½ÃÀåÀº 2030³â±îÁö 5¾ï 9,170¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 4¾ï 7,750¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 3.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 5¾ï 9,170¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ºÐ¼®±â´Â CAGR 4.3%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 4¾ï 1,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. ¼Ò¸ðǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 3,010¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 6.9%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â ½ÃÀåÀº 2024³â¿¡´Â 1¾ï 3,010¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 6.9%·Î 2030³â±îÁö 1¾ï 1,960¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.4%¿Í 2.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çö¹Ì°æÀ¸·Î º¸´Â Á¶±â ¹ß°ß: Áø´Ü ±â±â°¡ RA °ü¸®ÀÇ ¹Ì·¡¸¦ ¾î¶»°Ô Çü¼ºÇÒ °ÍÀΰ¡?

·ù¸¶Æ¼½º °üÀý¿°ÀÇ Á¶±â ¹× Á¤È®ÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä¸¦ °ßÀÎÇÏ´Â ¿äÀÎÀº ¹«¾ùÀϱî?

Àü ¼¼°è Àα¸ÀÇ ¾à 1%°¡ ¾Î°í ÀÖ´Â ¸¸¼º ÀÚ°¡¸é¿ªÁúȯÀÎ ·ù¸¶Æ¼½º°üÀý¿°(RA)ÀÇ Àü ¼¼°è ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å¼ÓÇϰí Á¤È®Çϸç Á¢±ÙÇϱ⠽¬¿î Áø´Ü µµ±¸ÀÇ Çʿ伺ÀÌ ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. RA´Â ÁøÇ༺, ºñ°¡¿ª¼º °üÀý ÁúȯÀ̱⠶§¹®¿¡ Àå±âÀûÀÎ Àå¾Ö¸¦ ¿¹¹æÇϰí ȯÀÚÀÇ »îÀÇ ÁúÀ» °³¼±ÇÏ¸ç °æÁ¦Àû ºÎ´ãÀ» ÁÙÀ̱â À§Çؼ­´Â Á¶±â Áø´ÜÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª ±âÁ¸ÀÇ Áø´Ü ÀÏÁ¤À¸·Î´Â Áõ»ó ¹ßÇöºÎÅÍ ÀÓ»óÀû È®ÀαîÁö 6°³¿ù ÀÌ»óÀÇ Áö¿¬ÀÌ ¹ß»ýÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·¯ÇÑ °ÝÂ÷·Î ÀÎÇØ RA¸¦ Á¶±â¿¡ ¹ß°ßÇÏ°í ´Ù¸¥ °üÀý¿°À̳ª ±Ù°ñ°Ý°è Áúȯ°ú ±¸º°ÇÒ ¼ö ÀÖ´Â Áø´Ü ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

±âÁ¸ÀÇ RA Áø´ÜÀº ÀÓ»óÀû Æò°¡, ·ù¸¶Æ¼½º ÀÎÀÚ(RF) Ç×ü ¹× Ç×°í¸®Çü ½ÃÆ®·ê¸°È­ ÆéŸÀ̵å(Ç×CCP) Ç×ü °Ë»ç, X-ray, MRI µîÀÇ ¿µ»ó Áø´ÜÀÌ ÀϹÝÀûÀ̾ú½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ¼ö´ÜµéÀº Ãʱ⠴ܰ迡¼­´Â ¹Î°¨µµ³ª ƯÀ̵µ¿¡ ÇѰ谡 ÀÖ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ¿¡ µû¶ó RA Áø´ÜÀ» ½Å¼ÓÇÏ°í °­È­Çϱâ À§ÇØ ¸ÖƼÇ÷º½º ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâ, POC(Point of Care) ±â´É, ÷´Ü ¿µ»ó Áø´Ü ¾Ë°í¸®ÁòÀ» Á¢¸ñÇÑ Â÷¼¼´ë Áø´Ü ±â±âÀÇ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. Ç÷ûÇÐÀû, ºÐÀÚÇÐÀû, ¿µ»ó Áø´Ü ±â¼úÀÇ À¶ÇÕÀº ÀÏÂ÷, ÀÌÂ÷, »ïÂ÷ ÀÇ·á¿¡¼­ º¸´Ù °³ÀÎÈ­µÈ µ¥ÀÌÅÍ ±â¹Ý Áø´Ü ÇÁ·ÎÅäÄÝÀÇ Åä´ë¸¦ ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¸¶Ä¿, ¿µ»ó Áø´Ü, ÇöÀå Áø·á ±â±âÀÇ Çõ½ÅÀÌ RA Áø´ÜÀ» ¾î¶»°Ô ÀçÁ¤ÀÇÇϰí Àִ°¡?

RA Áø´ÜÀÇ ±â¼ú ¹ßÀüÀº Áúº´ °ËÃâÀÇ Á¤È®¼º, ¼Óµµ, Á¢±Ù¼º È®´ë¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ELISA Ç÷§ÆûÀ̳ª ¹Ì¼¼À¯Ã¼ °Ë»ç īƮ¸®Áö¿Í °°Àº ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý ¸é¿ªºÐ¼® ±â±â´Â ÇöÀç ÇÑ ¹øÀÇ Ç÷¾× »ùÇÿ¡¼­ ¿©·¯ ¹ÙÀÌ¿À¸¶Ä¿(RF, Ç× CCP, CRP, CRP, ESR, 14-3-3η ´Ü¹éÁú)¸¦ °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸ÖƼÇ÷º½º ºÐ¼®Àº ƯÈ÷ Ãʱ⠶Ǵ Ç÷û À½¼ºÀÎ RA ȯÀÚ¿¡¼­ Áø´Ü ¹Î°¨µµ¸¦ Çâ»ó½ÃÄ×½À´Ï´Ù. °í󸮷® ½ÇÇè½Ç¿ë ºÐ¼® ±â±â´Â ÀÓ»ó Áõ»óÀÌ ¿ÏÀüÈ÷ ³ªÅ¸³ª±â ÀüÀÌ¶óµµ Ãʱâ RA¸¦ ³ªÅ¸³»´Â ÆÐÅÏ¿¡ Ç÷¡±×¸¦ Ç¥½ÃÇϱâ À§ÇØ AI¸¦ Ȱ¿ëÇÑ ºÐ¼®°ú ÅëÇյǰí ÀÖ½À´Ï´Ù. ÇÑÆí, ÈÞ´ë¿ë POC ºÐ¼®±â´Â ÀÏÂ÷ Áø·á ¹× Áö¿ª Ŭ¸®´Ð¿¡¼­ ³Î¸® º¸±ÞµÇ°í ÀÖÀ¸¸ç, Àǻ簡 ¸î ºÐ ¾È¿¡ RA¸¦ È®ÀÎÇϰųª ¹èÁ¦ÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù.

÷´Ü ¿µ»ó Áø´Ü ±â¼úµµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. µµÇ÷¯ ±â´ÉÀ» °®Ãá ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ(MSUS)´Â Ȱ¸· ¿°Áõ Æò°¡, »ý°Ë À¯µµ, Áúº´ ÁøÇà ¸ð´ÏÅ͸µ¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÁøÇà ´Ü°è¿¡¼­¸¸ ±¸Á¶Àû ¼Õ»óÀ» µå·¯³»´Â ¿¢½º·¹ÀÌ¿Í ´Þ¸®, ÃÊÀ½ÆÄ ¹× MRI´Â Áúº´ÀÇ Ãʱ⠴ܰ迡¼­ Ȱ¸·¿°°ú °ñ¼ö ºÎÁ¾À» °¨ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. AI¸¦ ÅëÇÑ ¿µ»ó °­È­ ¹× ÀÚµ¿ °üÀý Á¡¼öÈ­ ±â´ÉÀ» °®Ãá ±â±â´Â Áø´Ü Á¤È®µµ¸¦ ³ôÀ̰í, Àü¹® ±³À°À» ¹ÞÁö ¾ÊÀº ÀÓ»óÀǵµ ¿µ»ó Áø´Ü °á°ú¸¦ È¿°úÀûÀ¸·Î ÇØ¼®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ¶ÇÇÑ, °Ë»ç µ¥ÀÌÅÍ¿Í ¿µ»ó µ¥ÀÌÅ͸¦ ¼ÒÇÁÆ®¿þ¾î·Î ÅëÇÕÇÏ¿© Áø´Ü ÀÇ»ç°áÁ¤ Áö¿ø½Ã½ºÅÛÀ» ±¸ÃàÇÏ´Â °ÍÀº º´¿ø ȯ°æ¿¡¼­ º¸ÆíÈ­µÇ°í ÀÖÀ¸¸ç, Á¶±â °³ÀÔ Àü·«À» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ±â±âÀÇ ¼ÒÇüÈ­¿Í ½º¸¶Æ®Æù°úÀÇ ÅëÇÕÀ¸·Î °¡Á¤ ³» »ç¿ë ¹× ¿ø°ÝÁö¿¡¼­ÀÇ ·ù¸¶Æ¼½º Áø·á¸¦ À§ÇÑ ÈÞ´ë¿ë Áø´Ü ½Ã½ºÅÛ °³¹ßÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. °üÀýÀÇ ¿òÁ÷ÀÓ°ú ¿Âµµ, °£Áú¾× ³» ¿°Áõ ¸¶Ä¿¸¦ Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ´Â ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­´Â ½ÇÇè ´Ü°è¿¡ ÀÖÀ¸¸ç, °¡±î¿î ½ÃÀÏ ³»¿¡ ±âÁ¸ Áø´Ü¹ýÀ» º¸¿ÏÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº Áúº´ Ȱµ¿¼ºÀ» º¸´Ù Áö¼ÓÀûÀ¸·Î ÆÄ¾ÇÇÏ¿© Ä¡·á °³ÀÔÀÇ Å¸À̹ÖÀ» °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

Áö¿ª ÀÇ·á ÀÎÇÁ¶ó¿Í Áø´Ü °æ·Î°¡ ±â±â µµÀÔ¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?

RA Áø´Ü ±â±âÀÇ µµÀÔÀº Áö¿ª ³» ÀÇ·á ÀÎÇÁ¶ó, Áúº´ ÀÎÁöµµ, Àü¹® ÀÇ·á ¼­ºñ½º Á¢±Ù¼º¿¡ Å« ¿µÇâÀ» ¹Þ½À´Ï´Ù. ¹Ì±¹, µ¶ÀÏ, ÀϺ», ¿µ±¹ µî °í¼Òµæ ±¹°¡¿¡¼­´Â º¸ÇèÀÌ Àû¿ëµÇ°í ·ù¸¶Æ¼½º³»°ú ³×Æ®¿öÅ©°¡ Àß °®ÃçÁ® ÀÖ¾î Á¶±â Áø´ÜÀÌ ¿ëÀÌÇÕ´Ï´Ù. À̵é Áö¿ªÀÇ Áø´Ü °Ë»ç½ÇÀº ´ëºÎºÐ ÀüÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â·Î ¿î¿µµÇ°í ÀÖÀ¸¸ç, º´¿øÀº ÷´Ü ¿µ»ó Áø´Ü ±â±â¸¦ °®Ãß°í ÀÖ½À´Ï´Ù. ÀÓ»ó °¡À̵å¶óÀο¡¼­ Á¶±â ÀÇ·Ú¿Í Áø´ÜÀ» °­Á¶Çϰí ÀÖ¾î, °íÁ¤¹Ð °Ë»ç ¹× ¿µ»ó Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À̵é Áö¿ªÀÇ ÀÇ·á ½Ã½ºÅÛÀº ÀüÀÚ ÀÇ·á ±â·Ï(EMR)¿¡ Áø´Ü¹ýÀ» Àû±ØÀûÀ¸·Î ÅëÇÕÇÏ¿© Á¾´ÜÀû Áúº´ ÃßÀû ¹× ¿¬±¸¸¦ °¡´ÉÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.

¹Ý¸é ½ÅÈï±¹¿¡¼­´Â RA Áø´Ü »óȲÀÌ ´õ ´ÜÆíÀûÀÔ´Ï´Ù. Àεµ, ºê¶óÁú, Àεµ³×½Ã¾Æ µî¿¡¼­´Â ³·Àº ÀÎÁöµµ, ·ù¸¶Æ¼½º Àü¹®ÀÇ ºÎÁ·, °í±Þ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼º ºÎÁ· µîÀ¸·Î ÀÎÇØ Áø´ÜÀÌ Áö¿¬µÇ´Â °æ¿ì°¡ ¿©ÀüÈ÷ ÈçÇÕ´Ï´Ù. ±×·¯³ª ¸ð¹ÙÀÏ POC Áø´Ü ±â±â´Â ÀÌ·¯ÇÑ »óȲ¿¡¼­ Áß¿äÇÑ ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, Áø´ÜÀ» ºÐ»ê½ÃŰ°í µµ½Ã¿Í ³óÃÌÀÇ °ÝÂ÷¸¦ ÁÙÀÌ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯ ¹ß°ß¿¡ ÃÊÁ¡À» ¸ÂÃá Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê¿Í ¹Î°ü ÆÄÆ®³Ê½Êµµ ÀÏÂ÷ÀÇ·á¼¾ÅͰ¡ ±âº»ÀûÀÎ Áø´Ü ÀÎÇÁ¶ó¸¦ °®Ãß´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Áø´Ü ±â±â º¥´õÀÇ ¿ªÇÒÀº ÀÌ·¯ÇÑ Áö¿ªÀû °úÁ¦¿¡ µû¶ó º¯È­Çϰí ÀÖ½À´Ï´Ù. °¢ Á¦Á¶¾÷üµéÀº ÁýÁß ½ÇÇè½Ç, À§¼º Ŭ¸®´Ð, ¿ø°Ý °ËÁø Ä·ÇÁ¿¡ ÀûÀÀÇÒ ¼ö ÀÖ´Â È®Àå °¡´ÉÇÑ ±â±â Ç÷§ÆûÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿ø°ÝÀÇ·á Á¦°øÀÚ¿ÍÀÇ Á¦ÈÞ¸¦ ÅëÇØ ¿µ»ó ¾÷·Îµå ¹× Ç÷ûÇÐÀû °Ë»ç °á°úÀÇ ÀÚµ¿ Ç÷¡±ë¿¡ ´ëÀÀÇÏ´Â ·ù¸¶Æ¼½º Àü¹®ÀÇÀÇ ¿ø°Ý Áø´Ü Æò°¡°¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, Á¶±â Áø´ÜÀ» ÅëÇÑ ºñ¿ë Àý°¨À» µÞ¹ÞħÇÏ´Â ÀÇ·á °æÁ¦ÇÐÀû Áõ°Å´Â ÁöºÒÀÚ¿Í Á¤Ã¥ ÀÔ¾ÈÀڵ鿡°Ô Áø´Ü Çõ½Å¿¡ ´ëÇÑ ÅõÀÚ¸¦ µ¶·ÁÇϰí ÀÖ½À´Ï´Ù.

·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â ½ÃÀåÀÇ Àå±âÀûÀÎ ¼ºÀå µ¿·ÂÀº?

·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº Áúº´ À¯º´·ü Áõ°¡, RA º´Å»ý¸®¿¡ ´ëÇÑ ÀÌÇØµµ Çâ»ó, ÇコÄÉ¾î »ê¾÷ÀÇ Á¶±â °³ÀÔ°ú ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÃàÀÔ´Ï´Ù. °¡Àå °­·ÂÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â Áúº´ Á¶Àý Ç×·ù¸¶Æ¼½ºÁ¦(DMARDs)¸¦ °¡´ÉÇÑ ÇÑ »¡¸®, ÀÌ»óÀûÀ¸·Î´Â Áõ»ó ¹ßÇö ÈÄ Ã¹ 3°³¿ù À̳»¿¡ ½ÃÀÛÇØ¾ß ÇÑ´Ù´Â °ÍÀÔ´Ï´Ù. Áø´Ü Áö¿¬À» ´ÜÃàÇϰí Á¶±â RA¸¦ È®ÀÎÇÒ ¼ö ÀÖ´Â Áø´Ü ±â±â´Â ÀÌ ÀÓ»óÀû ¸ñÇ¥¸¦ ´Þ¼ºÇÏ´Â µ¥ ÀÖ¾î ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¶ÇÇÑ, °¡Ä¡ ±â¹Ý ÀǷḦ ÁöÇâÇÏ´Â ¿òÁ÷ÀÓÀº Áø´ÜÀÇ Á¤È®¼º°ú À§Çèµµ °èÃþÈ­ µµ±¸¿¡ ´ëÇÑ ¿ä±¸¸¦ ÁõÆø½Ã۰í ÀÖ½À´Ï´Ù. ÀÇ·áºñ ÁöºÒÀÚ¿Í ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ Àå±âÀûÀÎ Àå¾Ö, ÀÔ¿ø, ¾àÁ¦ºñ Àý°¨À» ¸ñÇ¥·Î ÇÏ´Â °¡¿îµ¥, Áúº´ ÁøÇà°ú Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ ¿¹ÃøÀû ÀλçÀÌÆ®¸¦ Á¦°øÇÏ´Â ±â±â¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¿¹ÈÄ ¹ÙÀÌ¿À¸¶Ä¿ ÆÐ³ÎÀ» Æ÷ÇÔÇϰųª Ä¡·á ¾Ë°í¸®Áò°ú ÅëÇÕµÈ Áø´Ü Ç÷§ÆûÀº RAÀÇ Á¤¹ÐÀǷḦ ½ÇÇöÇÏ´Â °ÍÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¸¶Áö¸·À¸·Î, ¿ø°ÝÀÇ·á, ¸ð¹ÙÀÏ Å¬¸®´Ð, ÀçÅà ¸ð´ÏÅ͸µ¿¡ ÈûÀÔÀº ºÐ»êÇü ¿ø°Ý Áø´ÜÀÇ ºÎ»óÀ¸·Î RA °Ë»çÀÇ ¹üÀ§°¡ Àü¹® Ŭ¸®´ÐÀ» ³Ñ¾î È®´ëµÇ°í ÀÖ½À´Ï´Ù. µðÁöÅÐ Çコ ¿¡ÄڽýºÅÛ°ú ȣȯµÇ´Â Àú·ÅÇÑ °¡°ÝÀÇ ½Å¼ÓÇÑ °Ë»ç ±â±â´Â Áý´Ü °ËÁø, Á÷Àå °Ç°­ ÇÁ·Î±×·¥, ¸¸¼ºÁúȯ ¾Æ¿ô¸®Ä¡ ÀÌ´Ï¼ÅÆ¼ºê¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ÀÇ·á ½Ã½ºÅÛÀÌ Á¶±â °³ÀÔ, ºñ¿ë Àý°¨, ¸¸¼ºÁúȯ °ü¸®¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ´Â °¡¿îµ¥, ·ù¸¶Æ¼½º °üÀý¿° Áø´Ü ±â±â´Â Áö¼ÓÀûÀÎ Çõ½Å°ú ½ÃÀå ħÅõ¸¦ À§ÇÑ Å¼¼¸¦ °®Ãß°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ºÐ¼®±â, ¼Ò¸ðǰ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

°ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°è °íÀ¯ÀÇ SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Rheumatoid Arthritis Diagnostic Devices Market to Reach US$591.7 Million by 2030

The global market for Rheumatoid Arthritis Diagnostic Devices estimated at US$477.5 Million in the year 2024, is expected to reach US$591.7 Million by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Analyzers, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$419.5 Million by the end of the analysis period. Growth in the Consumables segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$130.1 Million While China is Forecast to Grow at 6.9% CAGR

The Rheumatoid Arthritis Diagnostic Devices market in the U.S. is estimated at US$130.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$119.6 Million by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Rheumatoid Arthritis Diagnostic Devices Market - Key Trends & Drivers Summarized

Early Detection Under the Microscope: How Diagnostic Devices Are Shaping the Future of RA Management

What Is Driving the Demand for Early and Accurate Diagnosis in Rheumatoid Arthritis?

The rising global burden of rheumatoid arthritis (RA), a chronic autoimmune condition affecting approximately 1% of the global population, is driving the need for rapid, accurate, and accessible diagnostic tools. RA’s progressive nature and irreversible joint damage necessitate early diagnosis to prevent long-term disability, improve patient quality of life, and reduce the economic burden of care. Yet, conventional diagnostic timelines often lead to delays of six months or more between symptom onset and clinical confirmation. This gap has created significant demand for diagnostic devices that can detect RA earlier in its course and distinguish it from other forms of arthritis or musculoskeletal disorders.

Traditional diagnostic pathways for RA typically involve clinical evaluation, laboratory testing for rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies, and imaging modalities such as X-ray or MRI. However, these tools are often limited by sensitivity or specificity in early disease stages. In response, next-generation diagnostic devices are being developed to incorporate multiplex biomarker detection, point-of-care (POC) capabilities, and advanced imaging algorithms to accelerate and enhance RA diagnosis. The convergence of serological, molecular, and imaging technologies is laying the foundation for more personalized and data-driven diagnostic protocols across primary, secondary, and tertiary care settings.

How Are Innovations in Biomarkers, Imaging, and Point-of-Care Devices Redefining RA Diagnostics?

Technological advancements in RA diagnostics are focused on expanding the accuracy, speed, and accessibility of disease detection. Biomarker-based immunoassay devices, such as ELISA platforms and microfluidic test cartridges, are now capable of detecting multiple biomarkers-RF, anti-CCP, CRP, ESR, and 14-3-3η protein-from a single blood sample. These multiplex assays are improving diagnostic sensitivity, particularly in early or seronegative RA cases. High-throughput lab analyzers are being integrated with AI-powered analytics to flag patterns indicative of early RA, even before clinical symptoms fully manifest. Meanwhile, portable POC analyzers are gaining traction in primary care and community clinics, allowing physicians to confirm or rule out RA within minutes.

Advanced imaging technologies are also playing a critical role. Musculoskeletal ultrasound (MSUS) with Doppler capabilities is increasingly used for assessing synovial inflammation, guiding biopsies, and monitoring disease progression. Unlike X-rays, which only reveal structural damage in advanced stages, ultrasound and MRI can detect synovitis and bone marrow edema early in the disease. Devices with AI-based image enhancement and automated joint scoring are enhancing diagnostic precision and enabling clinicians with less specialized training to interpret imaging results effectively. Moreover, software-assisted integration of lab and imaging data into diagnostic decision-support systems is becoming common in hospital settings, supporting early intervention strategies.

Furthermore, device miniaturization and smartphone integration are fueling the development of portable diagnostic systems for home use and remote rheumatology services. Wearable biosensors that continuously monitor joint movement, temperature, or inflammatory markers in interstitial fluid are in experimental phases and could soon supplement traditional diagnostics. These innovations aim to create a more continuous, real-world understanding of disease activity and improve the timing of therapeutic interventions.

How Do Regional Healthcare Infrastructure and Diagnostic Pathways Impact Device Adoption?

The adoption of RA diagnostic devices is heavily influenced by local healthcare infrastructure, disease awareness levels, and access to specialized care. In high-income countries like the U.S., Germany, Japan, and the U.K., robust insurance coverage and rheumatology networks facilitate early diagnostic workups. Diagnostic laboratories in these regions often operate with fully automated immunoassay analyzers, and hospitals are equipped with advanced imaging modalities. Clinical guidelines emphasize early referral and diagnosis, creating a steady demand for high-accuracy lab and imaging solutions. Moreover, health systems in these regions are actively integrating diagnostics into electronic medical records (EMRs), enabling longitudinal disease tracking and research.

In contrast, emerging economies face a more fragmented RA diagnostic landscape. In countries such as India, Brazil, and Indonesia, delayed diagnosis remains common due to lack of awareness, limited rheumatology specialists, and minimal access to advanced testing. However, mobile POC diagnostic devices are emerging as a critical solution in these contexts, helping to decentralize diagnosis and reduce urban-rural disparities. Government initiatives focused on chronic disease detection, along with public-private partnerships, are also helping to equip primary health centers with basic diagnostic infrastructure.

The role of diagnostic device vendors is shifting in response to these regional challenges. Manufacturers are offering scalable device platforms that can be adapted for centralized labs, satellite clinics, or remote screening camps. Partnerships with telemedicine providers are also enabling remote diagnostic evaluations by rheumatologists, supported by imaging uploads and auto-flagged serological test results. Additionally, health economic evidence supporting cost savings from early diagnosis is influencing payers and policymakers to invest in diagnostic innovation.

What Is Driving Long-Term Growth in the Rheumatoid Arthritis Diagnostic Devices Market?

The growth in the rheumatoid arthritis diagnostic devices market is driven by increasing disease prevalence, improved understanding of RA pathophysiology, and the healthcare industry’s pivot toward early intervention and personalized care. One of the strongest growth drivers is the need to initiate disease-modifying antirheumatic drugs (DMARDs) as early as possible, ideally within the first three months of symptom onset. Diagnostic devices that can shorten the diagnostic delay and confirm early-stage RA are central to achieving this clinical target.

Additionally, the movement toward value-based care is amplifying demand for diagnostic accuracy and risk stratification tools. As payers and providers aim to reduce long-term disability, hospitalization, and drug expenditure, there is growing interest in devices that offer predictive insights into disease progression and therapeutic response. Diagnostic platforms that include prognostic biomarker panels or integrate with treatment algorithms are being positioned as enablers of precision medicine in RA.

Finally, the rise of decentralized and remote diagnostics-fueled by telehealth, mobile clinics, and home-based monitoring-is expanding the reach of RA testing beyond specialty clinics. Low-cost, rapid test devices compatible with digital health ecosystems are enabling population screening, workplace health programs, and chronic disease outreach initiatives. As health systems globally focus on early intervention, cost containment, and chronic disease management, rheumatoid arthritis diagnostic devices are poised for sustained innovation and market penetration.

SCOPE OF STUDY:

The report analyzes the Rheumatoid Arthritis Diagnostic Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Analyzers, Consumables)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â